Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
- The regulation of GABA cell viability in psychotic disorders
- Involvement of GABA-B receptors in the thalamic processing of nociceptive information
- GABA-B receptor subunit expression: Pharmacological and physiological implications
- Epigenetic modulation of GABA-A receptors in psychiatric disorders
- From gene to behavior and back again: New perspectives on the GABA-A receptor subunit selectivity
- Modulation of inotropic GABA receptors by natural products
- A role for GABA in alcohol dependence
- GABA-A agonists and partial agonists: THIP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic
- GABA-A receptor epilepsy mutations
- Role of Na/K ratio in GABA transport
- Structure-activity studies and functional pharmacology of GABA transporters
- Structure, pharmacology, and function of GABA-A receptor subtypes
- Pharmacological characteristics of GABA uptake inhibitors
A great deal of progress has been made in defining GABA (gamma-aminobutyric acid) transmission in the brain. Volume 54 of the Advances in Pharmacology series has also provided new insights into fundamental features of neurotransmission in general, such as the importance of allosterism and coincident signaling in regulating receptor function and overall cellular activity. These studies have led to the design and development of new drugs and potential therapeutic agents.
Given the successes achieved over the first 50 years of GABA research, it is certain the 6th decade will yield its share of surprising discoveries and new insights. Published in this volume are articles providing thoughts and perspectives on this topic, some with the benefit of hindsight, others in the context of recent findings, but all with a hint, or prediction, of what the future holds as the secrets of GABA neurotransmission continue to unfold.
*GABA is an amino acid found in mammalian brain *Articles written by leading investigators in the field *Provides new insights into fundamental features of neurotransmission
Academics and researchers in neuroscience, genetics, pharmacology, biology, neurology, and physiology.
- No. of pages:
- © Academic Press 2006
- 26th July 2006
- Academic Press
- Hardcover ISBN:
- eBook ISBN:
PRAISE FOR THE SERIES "Recommended not only to pharmacologists but also to all those in related disciplines." -NATURE
Dr. S. J. Enna received his B.A. degree (1965, Biology) from Rockhurst University, Kansas City, Missouri and both his M.S. (1967, Pharmacology) and Ph.D. (1970, Pharmacology) degrees from the University of Missouri-Kansas City. Postdoctoral training in pharmacology was completed at the University of Texas Southwestern Medical School in Dallas, at F. Hoffmann La Roche in Basel, Switzerland, and the Department of Pharmacology and Experimental Therapeutics at Johns Hopkins University School of Medicine in Baltimore. Dr. Enna spent 10 years on the faculty at the University of Texas Medical School at Houston in the Departments of Pharmacology and Neurobiology. While at the University of Texas Dr. Enna was also a consultant for ICI USA, Inc., Merck, Sharp and Dohme Research Laboratories, Bristol Myers Corporation, and Panlabs, Inc. From 1986 1990, Dr. Enna was Senior Vice President and Scientific Director of Nova Pharmaceutical Corporation in Baltimore, and Executive Vice President from 1990 1992. He is currently Associate Dean for Research and Graduate Education as well as Professor of Physiology and of Pharmacology at the University of Kansas Medical School. Dr. Enna served as chair of the Department of Pharmacology, Toxicology and Therapeutics at the University of Kansas Medical School from 1992 to 2003. Other previous academic appointments include Lecturer in the Department of Neuroscience at The Johns Hopkins University School of Medicine in Baltimore and Adjunct Professor of Pharmacology at Tulane University School of Medicine in New Orleans.
Dr. Enna served for six years as editor of The Journal of Pharmacology and Experimental Therapeutics, and is currently co-editor of Current Protocols in Pharmacology. He is also Editor-in-Chief of Biochemical Pharmacology, Executive Editor-in-Chief of Pharmacology and Therapeutics and Series Editor of Advances in Pharmacology. Besides his editorships, Dr. Enna serves on the editorial boards of Brain Research, Life Sciences and CNS Drug Reviews. He has been the recipient of Research Career Development Awards from the National Institute of Mental Health and the National Institute for Neurological, Communicative Disorders and Stoke. Other awards include the John Jacob Abel Award and the Torald Sollmann Award from the American Society for Pharmacology and Experimental Therapeutics, the Daniel H. Efron Award from the American College of Neuropsychopharmacology, and a PhARMA Foundation Excellence Award. In recent years he has been a member of the Scientific Advisory Council of Abbott Laboratories, has served on the Board of Directors of the Life Sciences Research Office, and on the Scientific Advisory Board of the National Alliance for Autism Research. He is currently a member of the Basic Pharmacology Advisory Committee of the PhARMA Foundation. Dr. Enna has held many elective offices in professional societies including the presidency of the American Society for Pharmacology and Experimental Therapeutics (ASPET). Since 2006 he has served as Secretary General of the International Union of Basic and Clinical Pharmacology (IUPHAR).
Dr. Enna's research interests include neuropharmacology, neurochemistry and neuropsychiatric disorders. He has made significant contributions in defining the pharmacological and biochemical properties of neurotransmitter receptors, in particular those for GABA. He has also conducted research into the effects of hormones on neurotransmitter receptor function and receptor responses to psychotherapeutics, the development of receptor antagonists for NMDA, cholinergic muscarinic and bradykinin receptors, and the identification of the cellular components of coincident signaling in brain. Dr. Enna's research is described in over 200 published research reports, reviews, and book chapters. He has authored or edited over three dozen books on topics ranging from neuropharmacology in general, to neurotransmitter receptors and GABA.
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, USA
John Hopkins University; Department of Pharmacology, Baltimore, Maryland, U.S.A.
Ferid Murad was born in Whiting, Indiana. Working concurrently on an M.D. and Ph.D. in Pharmacology, Dr. Murad graduated with both degrees from Case Western Reserve University, Cleveland, Ohio, in 1965. His many honors include the Alfred S. Maschke Award for Clinical Excellence from Case Western Reserve University in 1965. He has held several distinguished positions, including Acting Chairman in the Department of Medicine and Acting Division Chief, Division of Respiratory Medicine at Stanford University. He currently is CEO and President of Molecular Geriatrics Corporation in Lake Bluff, Illinois. Dr. Murad is married and has five children.
University of Texas Medical School, Houston, U.S.A.
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.